How biologic treatments for psoriasis affect risk of anogenital warts
Official title: Influence of Anti-Psoriatic Biologic Therapies Targeting TNF-α and Interleukins 17 and 23 on the Risk of Development and Recurrence of Anogenital Warts: A Retrospective and Prospective Study With an Exploratory Component on HPV Vaccination Acceptability (CONDYPSO)
Run by Centre Hospitalier Universitaire Saint Pierre · NCT07234838 · Data updated 2026-11-12
We will see if biologic medicines for moderate-to-severe psoriasis change the chance of developing or having recurrent anogenital warts.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Saint Pierre Academic / other |
| Drugs / interventions | ustekinumab, risankizumab, guselkumab, tildrakizumab, deucravacitinib, methotrexate |
| Locations | 3 sites (Brussels, Brussels Capital and 2 other locations) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | August 1, 2028 |
| Study ends | August 1, 2028 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT07234838 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with moderate-to-severe psoriasis who are receiving or starting anti-TNF-α, anti-IL-17, or anti-IL-23 biologics and who have planned dermatology follow-up and can provide informed consent are ideal candidates.
✕Probably not a fit
People with severe immunosuppression from other causes, children, or patients not receiving biologic therapy for psoriasis are unlikely to get directly relevant information from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project combines retrospective chart review with prospective, routine follow-up to compare new and recurrent anogenital wart rates in patients treated with anti-TNF-α, anti-IL-17, or anti-IL-23 therapies for moderate-to-severe psoriasis. Clinical data, treatment histories, and wart diagnoses/recurrences will be collected from medical records and during planned dermatology visits over about 24 months without extra study visits. The underlying rationale is that inhibiting Th1 and Th17 pathways could reduce local antiviral responses to HPV at the genital mucosa and thus alter wart persistence or recurrence. Analyses will estimate incidence and recurrence risks by biologic class while adjusting for relevant confounders.
Why it matters
Potential benefit: If successful, the results could help clinicians choose or monitor biologic therapies with lower risk of anogenital warts and guide HPV-related prevention or screening in psoriasis patients.
How similar studies have gone: Previous data are limited and mixed: small or cross-sectional analyses have not consistently shown increased anogenital HPV or wart rates in biologic-treated patients, so definitive evidence is still lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Moderate to severe psoriasis (BSA \> 10% or PASI \> 10), prior to initiation of the current therapy at the time of inclusion * Planned dermatological follow-up for approximately 24 months, with no additional visits required by the study * Signed informed consent Exclusion Criteria: * Severe immunosuppression not related to psoriasis or its therapy (concomitant treatment with major immunosuppressants, uncontrolled HIV infection, or other conditions inducing significant immunosuppression)
Where it's running
-
CHU Saint-Pierre
Brussels, Brussels Capital, Belgium Recruiting -
CHU Brugmann
Brussels, Brussels Capital, Belgium Recruiting -
Hôpital Erasme
Brussels, Brussels Capital, Belgium Recruiting
Study contacts
- Principal investigator: Jonathan Krygier, MD — Chu Saint-Pierre Bruxelles
- Study coordinator: Jonathan Krygier, MD
- Email: jonathan.krygier@stpierre-bru.be
- Phone: 025358385
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HB0017 Injection safety and PK in low-weight adults at different injection sites
This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.
-
MK-8644: first-in-human test in healthy people and people with psoriasis
This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care
This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
SHR-1139 injectable treatment for adults with plaque psoriasis
This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.